vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and TRUPANION, INC. (TRUP). Click either name above to swap in a different company.
TRUPANION, INC. is the larger business by last-quarter revenue ($376.9M vs $247.1M, roughly 1.5× ANI PHARMACEUTICALS INC). On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 11.7%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $25.3M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 11.0%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
TRUPANION, INC.TRUPEarnings & Financial Report
Trupanion, Inc. is a pet insurance provider headquartered in Seattle, Washington. Established in 1998, Trupanion operates across the United States, Canada, Australia, and Puerto Rico. The company offers coverage for pets and is self-underwritten by the American Pet Insurance Company (APIC).
ANIP vs TRUP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $376.9M |
| Net Profit | $27.5M | — |
| Gross Margin | — | 17.3% |
| Operating Margin | 14.1% | 1.9% |
| Net Margin | 11.1% | — |
| Revenue YoY | 29.6% | 11.7% |
| Net Profit YoY | 367.5% | — |
| EPS (diluted) | $1.14 | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $376.9M | ||
| Q3 25 | $227.8M | $366.9M | ||
| Q2 25 | $211.4M | $353.6M | ||
| Q1 25 | $197.1M | $342.0M | ||
| Q4 24 | $190.6M | $337.3M | ||
| Q3 24 | $148.3M | $327.5M | ||
| Q2 24 | $138.0M | $314.8M | ||
| Q1 24 | $137.4M | $306.1M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | — | ||
| Q2 25 | $8.5M | — | ||
| Q1 25 | $15.7M | — | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | — | ||
| Q2 24 | $-2.3M | — | ||
| Q1 24 | $18.2M | — |
| Q4 25 | — | 17.3% | ||
| Q3 25 | — | 16.4% | ||
| Q2 25 | — | 15.5% | ||
| Q1 25 | — | 14.9% | ||
| Q4 24 | — | 15.7% | ||
| Q3 24 | — | 15.1% | ||
| Q2 24 | — | 12.8% | ||
| Q1 24 | — | 11.8% |
| Q4 25 | 14.1% | 1.9% | ||
| Q3 25 | 15.9% | 1.6% | ||
| Q2 25 | 6.6% | 0.7% | ||
| Q1 25 | 13.3% | -0.4% | ||
| Q4 24 | -2.3% | 0.1% | ||
| Q3 24 | -13.8% | 0.5% | ||
| Q2 24 | 3.7% | -1.7% | ||
| Q1 24 | 14.8% | -2.0% |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 4.0% | — | ||
| Q1 25 | 8.0% | — | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | — | ||
| Q2 24 | -1.7% | — | ||
| Q1 24 | 13.2% | — |
| Q4 25 | $1.14 | $0.13 | ||
| Q3 25 | $1.13 | $0.13 | ||
| Q2 25 | $0.36 | $0.22 | ||
| Q1 25 | $0.69 | $-0.03 | ||
| Q4 24 | $-0.45 | $0.04 | ||
| Q3 24 | $-1.27 | $0.03 | ||
| Q2 24 | $-0.14 | $-0.14 | ||
| Q1 24 | $0.82 | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $370.7M |
| Total DebtLower is stronger | — | $101.8M |
| Stockholders' EquityBook value | $540.7M | $383.9M |
| Total Assets | $1.4B | $915.0M |
| Debt / EquityLower = less leverage | — | 0.27× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $370.7M | ||
| Q3 25 | $262.6M | $348.5M | ||
| Q2 25 | $217.8M | $319.6M | ||
| Q1 25 | $149.8M | $321.8M | ||
| Q4 24 | $144.9M | $307.4M | ||
| Q3 24 | $145.0M | $293.1M | ||
| Q2 24 | $240.1M | $277.2M | ||
| Q1 24 | $228.6M | $275.2M |
| Q4 25 | — | $101.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $127.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $383.9M | ||
| Q3 25 | $505.8M | $368.6M | ||
| Q2 25 | $436.8M | $355.5M | ||
| Q1 25 | $418.6M | $333.7M | ||
| Q4 24 | $403.7M | $323.3M | ||
| Q3 24 | $405.9M | $320.2M | ||
| Q2 24 | $455.8M | $305.8M | ||
| Q1 24 | $452.0M | $303.4M |
| Q4 25 | $1.4B | $915.0M | ||
| Q3 25 | $1.4B | $880.2M | ||
| Q2 25 | $1.3B | $847.8M | ||
| Q1 25 | $1.3B | $837.2M | ||
| Q4 24 | $1.3B | $806.9M | ||
| Q3 24 | $1.3B | $816.1M | ||
| Q2 24 | $920.8M | $795.9M | ||
| Q1 24 | $914.5M | $789.5M |
| Q4 25 | — | 0.27× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.39× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $29.3M |
| Free Cash FlowOCF − Capex | $29.1M | $25.3M |
| FCF MarginFCF / Revenue | 11.8% | 6.7% |
| Capex IntensityCapex / Revenue | 0.5% | 1.0% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $75.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $29.3M | ||
| Q3 25 | $44.1M | $29.2M | ||
| Q2 25 | $75.8M | $15.0M | ||
| Q1 25 | $35.0M | $16.0M | ||
| Q4 24 | $15.9M | $23.7M | ||
| Q3 24 | $12.5M | $15.3M | ||
| Q2 24 | $17.4M | $6.9M | ||
| Q1 24 | $18.3M | $2.4M |
| Q4 25 | $29.1M | $25.3M | ||
| Q3 25 | $38.0M | $23.9M | ||
| Q2 25 | $71.8M | $12.0M | ||
| Q1 25 | $32.5M | $14.0M | ||
| Q4 24 | $13.5M | $21.8M | ||
| Q3 24 | $7.7M | $13.4M | ||
| Q2 24 | $13.0M | $4.0M | ||
| Q1 24 | $13.7M | $-631.0K |
| Q4 25 | 11.8% | 6.7% | ||
| Q3 25 | 16.7% | 6.5% | ||
| Q2 25 | 34.0% | 3.4% | ||
| Q1 25 | 16.5% | 4.1% | ||
| Q4 24 | 7.1% | 6.5% | ||
| Q3 24 | 5.2% | 4.1% | ||
| Q2 24 | 9.4% | 1.3% | ||
| Q1 24 | 10.0% | -0.2% |
| Q4 25 | 0.5% | 1.0% | ||
| Q3 25 | 2.7% | 1.4% | ||
| Q2 25 | 1.9% | 0.8% | ||
| Q1 25 | 1.3% | 0.6% | ||
| Q4 24 | 1.3% | 0.6% | ||
| Q3 24 | 3.2% | 0.6% | ||
| Q2 24 | 3.2% | 0.9% | ||
| Q1 24 | 3.3% | 1.0% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
TRUP
| Subscriptionbusiness | $261.4M | 69% |
| Other | $115.4M | 31% |
